Inovio Pharmaceuticals (NASDAQ:INO) Coverage Initiated by Analysts at Stephens

Equities researchers at Stephens initiated coverage on shares of Inovio Pharmaceuticals (NASDAQ:INOGet Free Report) in a research report issued on Tuesday, MarketBeat Ratings reports. The brokerage set an “overweight” rating and a $20.00 price target on the biopharmaceutical company’s stock. Stephens’ target price suggests a potential upside of 76.06% from the company’s current price.

Other analysts have also recently issued research reports about the stock. Royal Bank of Canada reiterated a “sector perform” rating on shares of Inovio Pharmaceuticals in a research note on Thursday, March 7th. lowered shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, April 5th. Finally, Oppenheimer upgraded Inovio Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $48.00 target price for the company in a report on Thursday, January 25th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. Based on data from, the company currently has an average rating of “Hold” and a consensus target price of $70.67.

Read Our Latest Analysis on INO

Inovio Pharmaceuticals Trading Up 6.7 %

NASDAQ INO opened at $11.36 on Tuesday. The stock has a market cap of $265.48 million, a PE ratio of -1.50 and a beta of 1.16. Inovio Pharmaceuticals has a 12 month low of $3.89 and a 12 month high of $14.75. The stock’s 50 day moving average is $11.26 and its 200 day moving average is $37.27.

Hedge Funds Weigh In On Inovio Pharmaceuticals

A number of institutional investors have recently modified their holdings of INO. Susquehanna Fundamental Investments LLC purchased a new stake in Inovio Pharmaceuticals during the first quarter worth $1,482,000. Vanguard Personalized Indexing Management LLC boosted its holdings in shares of Inovio Pharmaceuticals by 5.6% in the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 115,361 shares of the biopharmaceutical company’s stock valued at $59,000 after buying an additional 6,148 shares in the last quarter. Keystone Financial Group lifted its position in Inovio Pharmaceuticals by 11.7% during the fourth quarter. Keystone Financial Group now owns 122,737 shares of the biopharmaceutical company’s stock valued at $63,000 after acquiring an additional 12,840 shares during the last quarter. Acadian Asset Management LLC purchased a new position in Inovio Pharmaceuticals in the third quarter worth $178,000. Finally, Pathstone Family Office LLC increased its position in shares of Inovio Pharmaceuticals by 344.2% during the third quarter. Pathstone Family Office LLC now owns 148,392 shares of the biopharmaceutical company’s stock worth $58,000 after purchasing an additional 114,989 shares in the last quarter. 26.79% of the stock is owned by hedge funds and other institutional investors.

About Inovio Pharmaceuticals

(Get Free Report)

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.

Featured Articles

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with's FREE daily email newsletter.